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An overview of the use of gold drugs in the alleviation
of the symptoms associated with the debilitating
disease rheumatoid arthritis (RA) is presented. Other
potential therapies based on gold compounds, such as
against parasitic diseases, HIV and asthma are
summarised. The development of gold compounds as
novel anti-tumour agents is also described.
Compounds containing gold(I), as utilised in the
treatment of RA, and gold(III), show exciting potential
in this regard, there being some very potent
compounds targeting biological targets, such as DNA,
and displaying selectivity in their cytotoxic profiles. In
conclusion, very real potential exists for the
development of anti-tumour agents based on gold.
Introduction
Regular readers of Gold Bulletin will be aware of the many
and varied applications of gold and its compounds. One only
has to look in the ‘Literature Highlights’ section of Gold
Bulletin to note advances in catalysis, nanotechnology,
electronics and medicine, to name but a few areas of active
research. Of these, it is the last-named endeavour, i.e. the use
of gold compounds in medicine, that forms the focus of this
overview.
The use of gold for medicinal purposes, real or perceived,
dates back to antiquity with Arabic, Indian and Chinese
physicians prescribing gold preparations for the treatment of
a variety of ailments; an historical perspective of the use of
gold or gold compounds in medicine is available (1) as is a
more recent survey of early Chinese use of gold (2). In more
recent times, gold compounds find clinical use as anti-
arthritic agents, i.e. chrysotherapy, as discussed below (3). In
addition, exploration continues into the potential use of gold
in the treatment of cancer (4), as anti-HIV (5) and anti-
malarial agents (6), and for the treatment of bronchial
asthma (7). The purpose of this review is to highlight the
current use of gold compounds in medicine and to
summarise current research directed towards developing
gold-based anti-tumour drugs.
Rheumatoid Arthritis and Treatments of
the Disease
Rheumatoid arthritis (RA) is one of over 100 arthritic diseases
afflicting humans with other common forms being
osteoarthritis and gout. RA accounts for about 5 - 10% of all
patients suffering arthritic diseases and is a particularly
debilitating form of arthritis. Manifestations of RA include
inflammation with concomitant restriction of movement and
pain of joints such as wrists, hands and feet. While the
disease can occur at any age, patients below 25 years are
relatively rare although the onset of the disease may occur at
an early age. There is no pattern of inheritance and females
are afflicted to a greater extent than men in the approximate
ratio 4:1. The aetiology of RA is not known although it is likely
due to a breakdown of the immune system. A patient is
usually diagnosed with RA if the following three factors are
satisfied: i) obvious inflammation, ii) erosion of the joints and
iii) presence of the rheumatoid factor associated with the
production of immunoglobulin. In summary, RA is a relatively
common and incapacitating disease with recognisable
manifestations but, one that is not well understood. Besides
the universal call to adopt better living standards, i.e. rest,
regular exercise and good diet, chemotherapy is at the
forefront of treatment.
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As the name suggests, DMARDS, act to impede or even stop
the progression of RA. These are appropriately employed for
newly-diagnosed patients so as to manage the disease by
halting progression. Examples of non-gold-based DMARDS
include Arava® (leflunomide), Azulfidine® (imuran), Cytoxan®
(cyclophosphamide), Novo-chloroquine® (chloroquine), and
Rheumatrex® (methotrexate). While there are the inevitable
side-effects associated with the above-named DMARDS, such
as flu-like symptoms, these are the price a patient has to pay in
order to retard the progression of the disease. As mentioned
above, gold-based compounds are also classed as DMARDS, as
there is experimental evidence to indicate that chrysotherapy
is disease modifying. However, it is fair to say that gold-drugs
are probably used more as a last-line of defence against RA.
Why this is so is not totally clear. Perhaps this represents a
general aversion to “heavy-metal therapy”. As discussed below,
there are side-effects associated with chrysotherapy but, this is
true for all chemotherapies. Having stated the above, there are
a number of gold-based drugs currently available for the
treatment of the symptoms associated with RA.
Chrysotherapy
There are two classes of gold compounds used in the
treatment of RA. Membership of each class relates to the
inherent chemistry of the compound and dictates their
Figure 1 
Chemical representations of (a) sodium aurothiomalate, (b) aurothioglucose, (c) sodium aurothiopropanol sulphonate, (d) sodium aurothiosulphate, 
and (e) auranofin
It should be stated from the outset that there is no cure for
RA; medication serves to alleviate pain and/or halt the
progression of the disease but, does not cure the disease. There
are several classes of drugs employed in the control of RA. The
first of these are Non-Steroidal Anti-Inflammatory Drugs
(NSAIDS). These function by blocking the production of
prostaglandins, the chemicals responsible for promoting pain
and inflammation. Amongst the NSAIDS that may be familiar to
readers are Advil® (ibuprofen), Feldene® (piroxicam), Lodine®
(etodolac), Naprosyn® (naproxen), and Voltaren® (diclofenac
sodium), to name but a few examples. However, NSAIDS do not
differentiate between the ‘good’ (i.e. prostaglandins that protect
kidney function and the stomach lining) and ‘bad’ prostaglandins
(that promote inflammation). Another relatively new class of
drugs are the COX-II enzyme inhibitors such as Celebrex®
(celecoxib), Mobic® (meloxicam) and Vioxx® (rofecoxib). These
drugs have selectivity in their mode of action in that they target
the inflammatory arthritis. The salicylates constitute another
important class of drugs used to relieve the pain and
inflammation associated with RA, of which Aspirin® is a notable
example. Glucocorticoids are drugs based on the naturally
occurring hormone, cortisone, and can rapidly act to reduce the
pain and swelling but, can induce serious side-effects such as
reducing resistance to infection, weight gain, loss of muscle
strength, cataracts, diabetes, osteoporosis, etc. The final class of
drugs to be briefly described, include gold compounds, and are
termed Disease-Modifying Antirheumatic Drugs, the DMARDS.
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mode of administration and therefore, biodistribution. The
first class of compounds are generally polymeric, charged
and water soluble. By contrast, the second class of
compound is monomeric, neutral and lipophilic. Class I
comprises (a) sodium aurothiomalate (e.g. Miocrin®,
Myochrysine®, Myocrisin®, Shiosol® & Tauredon®), (b)
aurothioglucose (e.g. Aureotan®, Auromyose®, & Solganol®),
(c) sodium aurothiopropanol sulphonate (Allochrysine
Limière®), and (d) sodium aurothiosulphate (Fosfocrisolo® &
Sanocrysin®). The chemical formulations of the above-
mentioned compounds are illustrated in Figure 1 but, these
are generally over-simplifications of the real structures, some
of which are, in fact, not yet known.
A crystal structure determination is available for
aurothiosulphate (8) as illustrated for the anion in Figure 2.
This monomeric structure demonstrates the propensity of
gold to exist in linear coordination geometries defined by
two sulphur atoms and in this way gives a clue to the
structures of the other gold drugs. Whereas there are two
potential sulphur donor atoms in aurothiosulphate, the ratio
of gold to sulphur in the remaining Class I compounds is 1:1
so that in order to achieve analogous S-Au-S entities, the
sulphur atoms in these structures must be bidentate and
bridging. Evidence in support of this conclusion has been
provided recently by the crystal structure determination of
the aurothiomalate anion in [Na2Cs(H)][{Au
(SCH(CO2)CH2CO2}2] (10). While this does not correspond to
the medicinal formulation in terms of the cations, the
polymeric array is consistent with expectation. As shown in
Figure 3, the gold atoms exist in linear geometries defined by
two sulphur atoms with this mode of association leading to
the formation of helical chains (with four-fold symmetry). By
contrast to the structural ambiguity associated with the Class
I compounds, the precise geometric structure is known 
for the sole member of the Class II drugs, 
i.e. triethylphosphinegold(I) tetraacetylatedthioglucose,
commonly known as auranofin (Aktil®, Crisinor®, Crisofin® &
Figure 2 
The molecular structure of the monomeric trianion found in the crystal
structure of sodium aurothiosulphate. The diagram was drawn with
DIAMOND® (9). Colour code: Gold, orange; sulphur, yellow; oxygen, red
Figure 3 
The molecular structure of the polymeric dianion found in the crystal
structure of [Na2Cs(H)][{Au(SCH(CO2)CH2CO2}2], an analogue of sodium
aurothiomalate. The diagram was drawn with DIAMOND® (9). Colour
code: Gold, orange; sulphur, yellow; oxygen, red; grey, carbon;
hydrogen, green
Figure 4 
The molecular structure of auranofin as determined by X-ray
crystallography. The diagram was drawn with DIAMOND® (9). Colour
code: Gold, orange; sulphur, yellow; phosphorus, pink; oxygen, red;
grey, carbon; hydrogen, green
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Ridaura®); structure (e) in Figure 1. The molecular structure of
auranofin as determined by X-ray crystallography (11) is
shown in Figure 4. The familiar linear coordination geometry
about gold is again featured. However, in this case only one
of the donor atoms is a sulphur atom as the other site is
occupied by a phosphorus atom derived from the
triethylphosphine ligand.
The above discussion may be summarised along the
following lines. RA is not a well understood disease that may
be treated but, not cured, by a variety of drugs, including
gold-based drugs, the structures for which are, generally, not
known. In the same way, the mechanism of action of gold-
drugs is not well understood. The following is a brief (and
simplified) précis of the possible metabolic pathways of the
Class I and II compounds.
As indicated above, owing to their chemical and physical
properties, Class I and II gold-drugs are administered
differently. The two most widely used Class I compounds in
chrysotherapy are sodium aurothiomalate and
aurothioglucose. These are typically administered by weekly
intramuscular injections of suspensions containing 50 mg of
‘gold’, after a two week induction period in which smaller
quantities of gold are delivered in order to monitor for side-
effects. Benefits from chrysotherapy using Class I drugs are
usually manifest after three to six months. Treatment can
result in a decrease in the painful swellings associated with
inflammation of joint linings and can prevent destruction of
bone and cartilage. Side-effects may appear immediately
upon treatment up to months after treatment has stopped
and may include dermatitis, discolouration of the skin,
metallic taste, diarrhoea, kidney and bone marrow
problems. The mode of administration of the Class I drugs
indicate that the drugs are delivered to the vascular system.
This is rich in the blood protein albumin and it is thought
that the gold drug undergoes a substitution reaction so that
one of the thiomalate ligands is replaced by an albumin
molecule. Subsequent metabolism may involve the
substitution of the second thiolate ligand of the drug by
another albumin molecule resulting in the original gold
atom existing within a ball of protein that is presumably
carried to the site of inflammation. Once at the diseased
site, the gold may be extracted by cyanide (a metabolite of
thiocyanate and generated at sites of inflammation) to form
a small anionic species that is known to have a very high
stability constant, i.e. [Au(CN)2]-. It may be that this is the
active species. A similar mechanism of action may be
envisaged for auranofin.
Auranofin is administered orally, typically in capsules
containing 3 – 6 mg ‘gold’, on a daily basis. This means that
auranofin is delivered to the gastrointestinal tract from which
approximately 25 – 30% of the gold is absorbed implying
that only small amounts of gold are retained by the body. It
appears that the gold-sulfur bond is readily cleaved and
albumin coordinated in its stead. The second step in the
metabolic pathway may involve coordination of another thiol
such as albumin or glutathione, reduction of the coordinated
albumin molecule and oxidation of the triethylphosphine to
triethylphosphineoxide. In this way, a gold protein complex is
generated as for the Class I drugs. The interested reader is
directed to reviews discussing the biochemistry of gold drugs
(3b, 12, 13). The obvious conclusion of what is known about
the metabolic pathways of both Class I and II drugs is they the
administered drugs rapidly undergo substitution reactions of
one sort or another and therefore, gold drugs must be
regarded as prodrugs.
Given the above, there is enormous scope for drug
development for the treatment of RA. For gold-based drugs,
outside his own work in this area, that has generated gold
compounds of significantly greater efficacy and reduced
toxicity (e.g. 14, 15), the author is not aware of other studies
directed towards developing new gold-based drugs in this
context. Nevertheless, there is great interest in developing
gold compounds as other therapies.
Other Therapeutic Potential of Gold
Compounds
As discussed above, the aetiology of RA is not known and
indeed many causes of the disease have been cited such as
induction by a simple mechanical knock. Possible biological
causes include malfunction in the immune system, viral and
bacterial infections. As such, gold compounds have been
evaluated for activity against other diseases owing to the
different possible causes of RA, as summarised below.
In the desperate quest to seek a cure for AIDS, some gold
drugs have been evaluated for activity against human
immunodeficiency virus (HIV). Early results suggest that there
might be some inhibition of HIV exhibited by gold compounds
such as sodium aurothiomalate and aurothioglucose (5, 16 -
19). Some gold compounds used in the treatment of RA have
also demonstrated effectiveness against severe bronchial
asthma owing to their immunosuppressant properties (7, 20,
21). Recent reviews describing new/different agents for
treating asthmatics suggest that gold-therapy might be
limited to severe cases (22 - 24), such as chronic
corticosteroid-dependent asthma, i.e. as second-line agents
as for the treatment of RA by DMARDS. Phosphinegold(I)
thiolates have also been evaluated for their activity against
parasitic diseases such as malaria (6) and Chagas disease (25).
However, in terms of drug development, most attention has
been devoted to the investigation of the anti-tumour
potential of gold compounds (4) and this forms the focus of
the remaining part of this review.
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Gold Compounds as Anti-Tumour Agents
There are several reasons as to why gold compounds should be
investigated for their potential as anti-tumour agents, based on
both the medical and chemical literature. First and foremost
was the dual biological activity exhibited by molecules such as
cyclophosphamide, 6-mercaptopurine and methotrexate.
These known anti-tumour agents also display
immunosuppressive and anti-inflammatory characteristics and
hence, their evaluation against RA was undertaken. This, in a
sense, establishes a connection between the two therapies,
even if tenuous. Allied to this were the results of a long-term
study of patients undergoing chrysotherapy (26). This study
suggested that such patients showed no enhanced risk or even
reduced risk of malignant diseases, a result that could be
correlated with the administration of gold drugs. Other factors
that suggest a study of the anti-tumour potential of gold
compounds might be worthwhile relates to the fact that gold
in the +3 oxidation state has the same electronic configuration
and structural characteristics as the World’s most widely-used
anti-cancer drug, cisplatin, i.e. (NH3)2PtCl2. The other main
reason relates to the observation, mentioned above, that gold
drugs are in fact prodrugs. In this regard, gold may be thought
of as a platform designed to deliver biologically active
molecules, i.e. drugs, to the body. Coordination of
biomolecules as such would obviously alter the normal
metabolic pathways, allow for slow-release mechanisms, etc.
and may lead to greater efficacy and reduced toxic side-effects
associated with organic molecules when administered alone.
Whatever the reasons for studying the anti-tumour potential of
gold compounds, the following discussion will demonstrate
that gold compounds display exciting cytotoxicity profiles,
based on in vitro assays, leading to interesting anti-tumour
activities, based on animal (in vivo) studies.
The first comprehensive studies of the anti-tumour
potential of gold compounds, including gold drugs, were
published in the mid- to late-1980’s [e.g. 27]. The
conclusions of these studies still have relevance today and are
worth restating. As a general principle to guide researchers in
this area, it was reported that gold compounds that were
active in vitro were not necessarily active in vivo, akin to other
studies, but, importantly, compounds that were inactive in
vitro were unlikely to be active in vivo. Hence, a rapid
screening of anti-tumour potential for gold compounds can
be achieved based on in vitro studies. A key outcome of this
early work was the conclusion that gold was essential for
elevated potency. These studies also showed that the most
promising class of compounds, at least containing gold(I),
were the phosphinegold(I) thiolates, i.e. related to the
structure of auranofin (Figure 4). Thus, gold(I) thiolates
related to the Class I anti-arthritic drugs were generally
inactive as were non-phosphine compounds and non-thiolate
compounds. In a sense, this was the first structure activity
relationship that was established: active compounds feature
the P-Au-S arrangement as found in the Class II RA drug,
auranofin. A subsequent study extended the range of gold
compounds to include those containing bidentate
phosphines (28, 29).
A particularly interesting observation was the
rearrangement, in solution and in biological media, of some of
the diphosphine compounds to yield a comparatively rare
coordination geometry, for gold(I), based on a tetrahedral
arrangement of four phosphorus donor atoms around gold as
illustrated in Figure 5 (30). These turned out to be a particularly
potent class of compounds but clinical trials were not pursued
owing to the acute toxicity associated with them. However,
subsequent studies have focused on chemically modifying the
aromatic substituents, such as to form n-pyridyl analogues, so
as to moderate the lipophilicity of the compounds and to
emphasise their apparent anti-mitochondrial activity; a recent
review summarises in more detail advances in this research
endeavour (31). Given the indications of the initial studies
examining the anti-tumour potential of gold compounds, i.e.
the potency of auranofin and analogues, it is perhaps not
surprising that the most significant effort has been devoted to
investigating the potential of auranofin analogues.
Given the fact that the clinically used gold compounds are
prodrugs, as mentioned a few times above, a logical
extension of earlier work was to couple phosphinegold(I)
species to biologically active thiols. This principle proved
fruitful in screening for anti-arthritic activity where thiols such
as 6-mercaptopurine and 6-thioguanine were utilised (14,
15); see above. These thiols are also known to possess anti-
cancer activity against human leukaemia and a study of the
potential anti-tumour activity of their phosphinegold(I)
compounds ensued. The prototype structure, i.e. of
triphenylphosphinegold(I) 6-mercaptopurinate, abbreviated
as Ph3PAu(6-MP), for these compounds is shown in Figure 6
(14). Several important conclusions were gained from the
study of these compounds (31-34).
As concluded from the earlier studies, it is clear that the
presence of the phosphinegold(I) entity enhances the
potency of the biologically-active thiols. Thus, greater overall
cytotoxicity was observed for the phosphinegold(I) thiolates
compared with the free thiols in a range of human cancer cell
lines. Further, the compounds showed greater potency than
cisplatin in these in vitro models, surely the benchmark in
metal-based anti-cancer treatment, as well as other standard
drugs. Preliminary anti-tumour screening, i.e. in vivo was also
conducted that showed that activity was maintained to a
certain extent (32). The principle of coupling therapeutically
important molecules to phosphinegold(I) entities is quite
clearly vindicated as may be seen from the data presented in
Table 1 (33). The results of the in vitro assay against a
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cisplatin-resistant leukaemia cell line (L1210/DDP)
demonstrate i) all compounds are more potent in this cell line
than cisplatin (a result consistent with the known anti-
leukaemia activity of 6-MPH) and ii) while each of the
Ph3PAuCl and 6-mercaptopurine (6-MPH) compounds show
potency, the most potent compound is the one that
combines both phosphinegold(I) and the anion derived from
6-MPH. Anti-tumour screening against PC6 plasmacytoma (a
cisplatin-sensitive murine cell line) showed that the Ph3PAu(6-
MP) significantly reduced the size of the tumour but not as
effectively as cisplatin. Importantly, this study showed that
promising in vitro results were maintained in an animal
model; it is noted that the relevance of animal tumours to
human tumours is debatable. Interest in these compounds
was sufficient to warrant a detailed examination of
cytotoxicity by the National Cancer Institute (U.S.A.) against a
panel of 60 cancer cell lines. Perhaps not surprising given the
known activity against leukaemia displayed by the thiols, 6-
mercaptopurine and 6-thioguanine, sub-panel selectivity
against leukaemia cell lines was observed. For the limited
series of phosphines examined when the thiolate derived
from 6-mercaptopurine constant, i.e. for the series of
compounds R3PAu(6-MP), a structure/activity relationship was
established in that the order of cytotoxicity was R =
cyclohexyl > ethyl > phenyl (33, 34). The apparent selectivity
for a particular cancer cell line, in this case, leukaemia, was
particularly encouraging and this theme is explored further
for the next series of compounds that were examined.
As part of an on-going attempt to alter the solubility
characteristics of phosphinegold(I) thiolates, an isomeric series
of n-mercaptobenzoates for n = 2-, 3- and 4-, were studied
(36, 37). For compounds of the general formula R3PAu(SC6H4-
CO2H-n), those with n = 2 were more cytotoxic than the n = 3
and n = 4 analogues. More exciting was the observation that
for the n = 2 series, several of the compounds displayed
selective activity against the A498 (renal cancer) and H226
(non-small cell lung cancer) cell lines, exhibited cytotoxicities
far better than cisplatin and were more potent or had
comparable potency to established anti-cancer compounds
such as doxorubicin and methotrexate (36, 37). On-going
studies are focusing on determining the maximum tolerated
doses and anti-tumour activities of these compounds; these
results will be published in due course but are most
encouraging. A recent review detailing the work emanating
from our own laboratories has just been published (38).
Thus far, the focus of discussion in this overview has been
upon gold(I) compounds. However, an area of research
gaining prominence, based on recent publications, features
gold(III) compounds. Gold(III) would normally be regarded as
oxidising and this property could be exacerbated in the
reducing mammalian environment. However, judicious
choice of donor atoms in the ligand donor set can impart
stability to the higher oxidation state; gold(III) is regarded as
an “harder” acid than gold(I) and hence, is more likely to
form stable compounds with donor atoms such as nitrogen
and oxygen whereas gold(I) exhibits a distinct preference for
sulphur and phosphorus donor atoms.
The gold(III) compounds investigated for potential anti-
tumour activity are inevitably four-coordinate and feature
square planar geometries, as found for cisplatin so that,
perhaps, a similar mechanism of action, i.e. interaction with
DNA and disruption of normal cellular processes, may be
assumed for these compounds. In this connection, evidence
has been provided showing that some species bind DNA (39).
There are basically three classes of gold(III) compounds
receiving serious attention at present. The three classes are i)
Compound IC50a Growth inhibitionb
6-MPHc 3.3 no effect
Ph3PAuClc 0.14 no effect
Ph3PAu(6-MP)d 0.05 60%
cisplatin 6.7 100%
a IC50 value in μM units - the amount of compound required to inhibit
50% growth of L1210/DDP leukaemia cancer cells; the smaller the
value, the greater the potency
b Percentage growth inhibition of PC6 tumours grown in female
Balb/C mice; the greater the value, the more effective the
compound
c 6-MPH is 6-mercaptopurine; Ph3P is triphenylphosphine
d The molecular structure of this compound is illustrated in Figure 6
Table 1 
Selected cytotoxicity and anti-tumour screening results
Figure 5 
The molecular structure of the [Au(dppe)2] + cation as determined by 
X-ray crystallography. The diagram was drawn with DIAMOND® (9).
Colour code: Gold, orange; phosphorus, pink; grey, carbon; 
hydrogen, green
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those incorporating biologically active species such as
streptonigrin (40); ii) compounds with imine (pyridine-type
nitrogen) donor atoms (41); and iii) organogold compounds,
i.e. containing Au-C bonds (42). Whereas the overwhelming
majority of gold(III) compounds investigated thus far contain
ligand donors derived from one or some combination of
chloride, nitrogen, oxygen, and carbon. Perhaps it is
significant that arguably the compound showing the most
promise contains a sulphur donor atom derived from 2-
mercaptobenzoate, See Figure 7 (42b), as found in their
phosphinegold(I) analogues discussed above.
Conclusions and Outlook
The above discussion describes some of the current
medicinal uses of gold compounds, namely in the
remediation of the symptoms associated with rheumatoid
arthritis. Other therapies based on gold may include their use
as anti- parasitic, -HIV and -asthma agents. Arguably the most
active research in medicinal gold chemistry involves the
development of novel anti-tumour agents. Three areas in
particular attract significant attention although there are
other strategies worth pursuing not mentioned above such
as for example heterometallic systems (4). The three areas
are i) developing tetrahedrally coordinated gold(I)
compounds that may target mitochrondria, ii) generating
phosphinegold(I) thiolates where the gold is employed as a
carrier of biologically-active substrates, and iii) forming
square planar gold(III) compounds that may also target DNA.
In fact, in terms of recent publications, gold(III) species are
receiving the most attention such as gold(III) porphyrin (43)
and aminoquinoline (44) derivatives. An interesting
development involves the three-coordinate gold(I) species
with both mono- and bi-dentate phosphine ligands (45). The
foregoing shows that i) there is still considerable interest, at
least amongst the academic community, in developing gold
compounds for anti-tumour screening, and ii) the variations
in gold compounds are far from exhausted with novel
compounds waiting to be generated.
In developing new anti-tumour agents, researchers should
be mindful of several factors required for the successful
adoption of new therapeutic agents such as the need to
target cisplatin-resistant cancer cell lines, to reduce
deleterious side-effects associated with chemotherapy and,
related to this, to target specific biological sites, i.e. to
increase the selectivity of the anti-cancer agents. However,
too strict an adherence to these principles might preclude
serendipitous discoveries, keeping in mind that the biological
activity of cisplatin was noted by keen experimental
observation rather than rational drug design. In terms of anti-
tumour screening, the most reliable biological evaluation will
be obtained from in vivo models of human cancer cell lines
but, only after mandatory in vitro cytotoxicity screening.
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